Shares of TherapeuticsMD Inc (NASDAQ:TXMD) have been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $14.86.
Several brokerages have recently commented on TXMD. Cantor Fitzgerald reaffirmed a “buy” rating and set a $28.00 price objective on shares of TherapeuticsMD in a research note on Sunday, January 7th. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Oppenheimer reiterated a “buy” rating and set a $10.00 price target on shares of TherapeuticsMD in a research report on Sunday, January 28th. Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $5.25 on Friday. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30. The stock has a market cap of $1,116.62, a price-to-earnings ratio of -13.82 and a beta of 1.36.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The business’s revenue for the quarter was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) earnings per share. equities analysts predict that TherapeuticsMD will post -0.38 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. MANA Advisors LLC bought a new position in shares of TherapeuticsMD in the fourth quarter worth approximately $104,000. Paloma Partners Management Co bought a new position in TherapeuticsMD during the fourth quarter valued at approximately $105,000. Edge Wealth Management LLC lifted its position in TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after purchasing an additional 20,000 shares during the period. Quantbot Technologies LP bought a new position in TherapeuticsMD during the third quarter valued at approximately $189,000. Finally, Claraphi Advisory Network LLC bought a new position in TherapeuticsMD during the fourth quarter valued at approximately $275,000. Hedge funds and other institutional investors own 73.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of “Buy” from Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/18/therapeuticsmd-inc-txmd-receives-consensus-recommendation-of-buy-from-brokerages.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.